カテゴリ： GlobalData, アメリカ, 企業調査

Onconova Therapeutics Inc (ONTX)：製薬・医療：M&Aディール及び事業提携情報

◆英語タイトル：Onconova Therapeutics Inc (ONTX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA904C9796
◆発行会社（調査会社）：GlobalData
◆発行日：2018年11月
◆ページ数：77
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：アメリカ
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Onconova Therapeutics Inc (Onconova) is a biopharmaceutical company that discovers and develops small molecule drug candidates for the treatment of cancer. The company’s drug candidates include rigosertib, briciclib and recilisib. It develops drug candidates that target cancer and protect healthy cells based on its proprietary chemistry platform and cell-based differential screening. Onconova’s rigosertib is targeted at meeting medical needs of patients with myelodysplastic syndromes. The company’s recilisib is used to treat the effects of acute radiation syndromes such as cytopenia. It partners with biopharmaceutical companies and medical organizations in the US. The company operates through its offices in Newtown and Pennington, the US. Onconova is headquartered in Newtown, Pennsylvania, the US.

Onconova Therapeutics Inc (ONTX) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Onconova Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Onconova Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Onconova Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Onconova Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Onconova Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Onconova Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
Onconova Therapeutics Raises US$50 Million In Venture Financing 11
Onconova Therapeutics Raises US$26.4 Million In Venture Financing Round 12
Partnerships 13
Onconova Therapeutics Enters into R&D Agreement with National Cancer Institute 13
Cellectar Biosciences Enters into Agreement with Onconova Therapeutics 14
Onconova Therapeutics Enters into Research Partnership with SymBio Pharma 15
GVK Biosciences Enters Into Agreement With Onconova Therapeutics To Develop New Cancer Drugs 16
Licensing Agreements 17
Pint Pharma Enters into Licensing Agreement with Onconova Therapeutics 17
HanX Biopharma Enters into Licensing Agreement with Onconova Therapeutics 18
Baxter International Enters into Licensing Agreement with Onconova Therapeutics 19
Equity Offering 20
Onconova Therapeutics Raises USD28.7 Million Public Offering of Shares and Warrants 20
Onconova Therapeutics Raises USD1.3 Million in Private Placement of Shares 22
Onconova Therapeutics Raises USD10 Million in Public Offering of Shares 23
Onconova Therapeutics Raises USD1.4 Million in Private Placement of Shares 25
Onconova Therapeutics Plans to Raise up to USD84.5 Million in Public Offering of Shares 26
Onconova Therapeutics Raises USD5.2 Million in Public Offering of Shares 27
Onconova Therapeutics Raises USD17.5 Million in Rights Offering of Units 28
Onconova Therapeutics Raises USD1.8 Million in Private Placement of Shares 30
Onconova Therapeutics Raises USD1.5 Million in Private Placement of Shares 31
Onconova Therapeutics Completes IPO Of Shares For US$89 Million 32
Onconova Therapeutics Inc – Key Competitors 34
Onconova Therapeutics Inc – Key Employees 35
Onconova Therapeutics Inc – Locations And Subsidiaries 36
Head Office 36
Other Locations & Subsidiaries 36
Recent Developments 37
Financial Announcements 37
Aug 14, 2018: Onconova Therapeutics reports business highlights and financial results for second quarter 2018 37
May 15, 2018: Onconova Therapeutics Reports Business Highlights and Financial Results for First Quarter 2018 39
Mar 08, 2018: Onconova Therapeutics Reports Business Highlights and Full Year 2017 Financial Results 40
Nov 09, 2017: Onconova Therapeutics Reports Third Quarter 2017 Financial Results 42
Aug 15, 2017: Onconova Therapeutics Reports Recent Business Highlights and Second Quarter 2017 Financial Results 43
May 15, 2017: Onconova Therapeutics Reports Recent Business Highlights and First Quarter 2017 Financial Results 45
Mar 27, 2017: Onconova Therapeutics Reports Recent Business Highlights and Year-end 2016 Financial Results 47
Corporate Communications 48
Nov 07, 2018: Onconova welcomes Richard Woodman, M.D., as Chief Medical Officer 48
Jun 21, 2018: Onconova Therapeutics Promotes Steven M. Fruchtman To President 49
Product News 50
11/15/2017: Onconova Therapeutics Announces Publication of Results from Phase 1/2 Study of Rigosertib in Patients with Myelodysplastic Syndromes (MDS) and MDS Progressed to Acute Myeloid Leukemia 50
07/25/2017: Onconova Therapeutics Announces Establishment of Collaborative Research and Clinical Programs Evaluating Rigosertib in Pediatric “RASopathies” 52
02/20/2018: Onconova Announces Presentation on its Acute Myeloid Leukemia Drug Candidate ON-150030 at 2018 American Chemical Society National Meeting and Expo 53
02/02/2018: Onconova Announces Presentation Of Mechanism Of Action Studies Of Rigosertib Combination With Azacitidine At American Association For Cancer Epigenetics Research Conference 54
Clinical Trials 55
Jan 17, 2018: Onconova Moving Forward with Phase 3 INSPIRE Pivotal Trial with Increased Sample Size Following Promising Interim Analysis 55
Dec 12, 2017: Onconova Presents Data on Rigosertib in Myelodysplastic Syndromes at the ASH 2017 Meeting 57
Nov 16, 2017: Onconova Therapeutics Announces Data on Improved Formulation of Rigosertib and Next-Generation CDK4/6 Inhibitor at 2017 American Association of Pharmaceutical Scientists Annual Meeting 59
Nov 09, 2017: Onconova Therapeutics Provides Update on Rigosertib 61
Nov 01, 2017: Onconova Announces Two Presentations on Rigosertib in Myelodysplastic Syndromes at the ASH 2017 Annual Meeting 64
Oct 10, 2017: Initiation of Patient Enrollment in the Phase 1 Clinical Trial of Single-Agent Oral Rigosertib in Higher-Risk Myelodysplastic Syndromes 65
Oct 04, 2017: Onconova to Host Key Opinion Leader Meeting on Novel Approaches to the Diagnosis and Treatment of Pediatric RASopathies on Wednesday, October 11, in New York City 66
Jun 30, 2017: SymBio Pharmaceuticals Announces Initiation in Japan of the Phase I Clinical Trial of Single-Agent Oral Rigosertib in Higher-Risk Myelodysplastic Syndromes 67
Jun 26, 2017: Onconova Therapeutics Presents Rigosertib Data at the 22nd Congress of the European Hematology Association in Madrid 68
Jun 05, 2017: Onconova Therapeutics Announces Positive Phase 2 Data in Rigosertib Treated Patients with Second-line Myelodysplastic Syndromes at the American Society of Clinical Oncology Annual Meeting 70
May 22, 2017: Onconova Announces Multiple Presentations at the 22nd Congress of the European Hematology Association 72
May 18, 2017: Onconova Therapeutics to Present a Poster Session Relating to Intravenous Rigosertib at the 2017 American Society of Clinical Oncology Annual Meeting 74
May 01, 2017: Onconova to Present Rigosertib Clinical Data at the 14th International Symposium on Myelodysplastic Syndromes 75
Apr 04, 2017: Onconova Therapeutics Announces Positive Preclinical Data on ON dual FLT3 and Src inhibitor 150030 at 2017 American Association of Cancer Research Annual Meeting 76
Appendix 77
Methodology 77
About GlobalData 77
Contact Us 77
Disclaimer 77

List of Tables
Onconova Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Onconova Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Onconova Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Onconova Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Onconova Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Onconova Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Onconova Therapeutics Raises US$50 Million In Venture Financing 11
Onconova Therapeutics Raises US$26.4 Million In Venture Financing Round 12
Onconova Therapeutics Enters into R&D Agreement with National Cancer Institute 13
Cellectar Biosciences Enters into Agreement with Onconova Therapeutics 14
Onconova Therapeutics Enters into Research Partnership with SymBio Pharma 15
GVK Biosciences Enters Into Agreement With Onconova Therapeutics To Develop New Cancer Drugs 16
Pint Pharma Enters into Licensing Agreement with Onconova Therapeutics 17
HanX Biopharma Enters into Licensing Agreement with Onconova Therapeutics 18
Baxter International Enters into Licensing Agreement with Onconova Therapeutics 19
Onconova Therapeutics Raises USD28.7 Million Public Offering of Shares and Warrants 20
Onconova Therapeutics Raises USD1.3 Million in Private Placement of Shares 22
Onconova Therapeutics Raises USD10 Million in Public Offering of Shares 23
Onconova Therapeutics Raises USD1.4 Million in Private Placement of Shares 25
Onconova Therapeutics Plans to Raise up to USD84.5 Million in Public Offering of Shares 26
Onconova Therapeutics Raises USD5.2 Million in Public Offering of Shares 27
Onconova Therapeutics Raises USD17.5 Million in Rights Offering of Units 28
Onconova Therapeutics Raises USD1.8 Million in Private Placement of Shares 30
Onconova Therapeutics Raises USD1.5 Million in Private Placement of Shares 31
Onconova Therapeutics Completes IPO Of Shares For US$89 Million 32
Onconova Therapeutics Inc, Key Competitors 34
Onconova Therapeutics Inc, Key Employees 35
Onconova Therapeutics Inc, Subsidiaries 36

List of Figures
Onconova Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Onconova Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Onconova Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Onconova Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Onconova Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Onconova Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Onconova Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Onconova Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[Onconova Therapeutics Inc (ONTX)：製薬・医療：M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • East African Breweries Ltd：企業の戦略・SWOT・財務分析
    East African Breweries Ltd - Strategy, SWOT and Corporate Finance Report Summary East African Breweries Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Advantagene Inc：製薬・医療：M&Aディール及び事業提携情報
    Summary Advantagene Inc (Advantagene) is a biopharmaceutical company. It manufactures, develops, and tests cancer immunotherapy drugs and gene-based biologics. It offers a proprietary Gene Mediated Cytotoxic Immunotherapy (GMCI), a platform technology designed to stimulate a patient’s immune system …
  • International Drug Development Institute-製薬・医療分野：企業M&A・提携分析
    Summary International Drug Development Institute (IDDI) is a healthcare institute that offers clinical data collection, analysis, trial design and trial reporting services. The institute offers biostatistical services and eClinical services and risk-based monitoring programs. Its biostatistical and …
  • Physio-Control Inc：医療機器：M&Aディール及び事業提携情報
    Summary Physio-Control Inc (Physio-Control), a subsidiary of Stryker Corp, is a manufacturer of emergency medical response products. The company offers lifepak monitor and defibrillator, lifepak CR plus AED, lifepak express AED, lifenet system, data review software, chest true cprcoaching device, lu …
  • Lutron Electronics Co Inc：企業の戦略的SWOT分析
    Lutron Electronics Co Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • Schneider National Inc (SNDR)：企業の財務・戦略的SWOT分析
    Schneider National Inc (SNDR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • Ten Network Holdings Ltd：企業の戦略的SWOT分析
    Ten Network Holdings Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products a …
  • Kobayashi Pharmaceutical Co Ltd (4967)：医療機器：M&Aディール及び事業提携情報
    Summary Kobayashi Pharmaceutical Co Ltd (Kobayashi) is a manufacturer and distributor of pharmaceutical, health and personal care products. The company offers OTC pharmaceuticals, oral hygiene products, deodorizing air fresheners, cooling gel sheets, sanitary products, household sundries, and body w …
  • Pear Therapeutics Inc：製薬・医療：M&Aディール及び事業提携情報
    Summary Pear Therapeutics Inc (Pear Therapeutics) develops software-based prescription digital therapeutics for the treatment of severe medical conditions and diseases. Its product pipeline includes reSET-O for treating opioid use disorder (OUD) in conjunction with opioid replacement therapy; Thrive …
  • Interface Biologics Inc：医療機器：M&Aディール及び事業提携情報
    Summary Interface Biologics Inc (IBI) is a medical device company that develops transformative biomedical polymer technologies. The company offers anti-thrombogenic and combination drug delivery devices. Its anti-thrombogenic additives reduce thrombosis in blood contacting medical devices and polyme …
  • Rajesh Exports Limited
    Rajesh Exports Limited - Strategy, SWOT and Corporate Finance Report Summary Rajesh Exports Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Janssen Diagnostics LLC-医療機器分野：企業M&A・提携分析
    Summary Janssen Diagnostics LLC (Janssen), formerly Veridex, LLC, a subsidiary of Johnson & Johnson is a medical device company that develops and markets diagnostics products and solutions for the healthcare markets. The company’s products include circulating tumor cell kit, CTC control kit, CellSav …
  • Yamaha Motor Co Ltd (7272)：企業の財務・戦略的SWOT分析
    Yamaha Motor Co Ltd (7272) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Wm Morrison Supermarkets PLC：企業のM&A・事業提携・投資動向
    Wm Morrison Supermarkets PLC - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Wm Morrison Supermarkets PLC Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and a …
  • ImaginAb Inc：製薬・医療：M&Aディール及び事業提携情報
    Summary ImaginAb Inc (ImaginAb) is an immune and oncology imaging company that develops in vivo antibody-based imaging agents. It is engaged in the discovery, development, and production of new compounds and products in human health and cosmetics, agriculture and food sectors. The company’s product …
  • Mississippi Power Co-エネルギー分野：企業M&A・提携分析
    Summary Mississippi Power Company (Mississippi Power), a subsidiary of Southern Company, is a vertically integrated electric utility which generates, procures, transmits, distributes, and sells energy. It produces power from coal and natural gas sources. Mississippi Power owns and operates fossil st …
  • Gilead Sciences Inc (GILD)：医療機器：M&Aディール及び事業提携情報
    Summary Gilead Sciences Inc (Gilead) is a research-based biopharmaceutical company. It focuses on the discovery, development and commercialization of medicines for the treatment of cardiovascular, hematological and respiratory diseases, inflammation, liver diseases, cancer and human immunodeficiency …
  • AgeneBio Inc：製薬・医療：M&Aディール及び事業提携情報
    Summary AgeneBio Inc (AgeneBio) is a pharmaceutical company that develops therapies for psychiatric and neurological diseases. The company’s therapy is targeted to prevent neurodegeneration and preserve and restore cognitive function for unserved patients. Its lead candidate AGB101 is under phase 3 …
  • Hanwha Chemical Corp (009830)：企業の財務・戦略的SWOT分析
    Summary Hanwha Chemical Corp (Hanwha), a subsidiary of Hanwha Corp is a chemical company that manufactures, develops, and distributes basic industrial chemicals, general purpose plastic products, and other chemical products. The company's chemical products include inorganic compounds, PVC, polymers, …
  • Icagen Inc：製薬・医療：M&Aディール及び事業提携情報
    Summary Icagen Inc (Icagen) (formerly known as XRpro Sciences, Inc.) is a biopharmaceutical company which develops drug candidates to unmet medical needs. The company discovers drug for clinical stage across multiple therapeutics and ion class channel classes. The company provides technologies inclu …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆